Analyst Ratings for Axovant Gene Therapies (AXGT)
Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
4/17/2020 | Cantor Fitzgerald | Kristen Kluska | New Coverage | Overweight (N/A) |
11.00 (N/A) |
3.45 (2.10) |
-39.13% | Details |
8/12/2019 | Baird | Brian Skorney | Upgrade | Outperform (Neutral) |
13.00 (16.00) |
6.61 (2.10) |
-68.23% | Details |